Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,394 result(s) found. Displaying page 1,752 of 2,220.
    «« First « Previous 1748  1749  1750  1751  1752  1753  1754  1755  1756  Next» Last»»
    EudraCT Number: 2015-003513-24 Sponsor Protocol Number: IN11004OLE Start Date*: 2016-05-24
    Sponsor Name:Intec Pharma, Ltd.
    Full Title: An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects who Completed Study IN 11 004
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10034005 Parkinson's disease and parkinsonism HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) DE (Completed) BG (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000235-40 Sponsor Protocol Number: STATIC-2016-000235-40 Start Date*: 2016-07-29
    Sponsor Name:Region Skåne
    Full Title: Stopping anti-TNF treatment in Crohn’s and Colitis patients in remission
    Medical condition: Crohn´s disease Ulcerative colitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002467-34 Sponsor Protocol Number: AIO-YMO/HEP-0315 Start Date*: 2017-07-19
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancer - An open label, non-comparative, randomized, multicenter phase II trial
    Medical condition: Locally advanced or metastatic, non resectable, adenocarcinoma of the biliary tract including intrahepatic and extrahepatic bile duct
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025734 Malignant neoplasm of biliary tract, part unspecified LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008594 Cholangiocarcinoma non-resectable LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028982 Neoplasm biliary tract LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077846 Cholangiocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001193-15 Sponsor Protocol Number: FASTERCC-001 Start Date*: 2016-07-06
    Sponsor Name:Department of Oncology, Aarhus University Hospital
    Full Title: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy (FASTERCC). A randomized, double-blind, phase II ...
    Medical condition: Mucositis (nasal, oral, pharyngeal, anal, or genital) is often experienced in relation to TKI and mTOR inhibitor treatment of metastatic renal cell carcinoma patients. The present trial will assess...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10064282 Vaginal mucositis LLT
    20.0 100000004856 10028130 Mucositis oral LLT
    20.0 100000004856 10065721 Anal mucositis LLT
    20.0 100000004867 10028127 Mucositis LLT
    20.0 100000004855 10065881 Pharyngeal mucositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005067-52 Sponsor Protocol Number: DPCG-01 Start Date*: 2022-02-10
    Sponsor Name:Aalborg University Hospital, Department of Oncology
    Full Title: A randomized phase II study of gemcitabine versus reduced-dose combination chemotherapy in fragile patients with non-resectable pancreatic cancer.
    Medical condition: Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002150-12 Sponsor Protocol Number: DANSVIGT Start Date*: 2017-10-11
    Sponsor Name:Danish Society of Cardiology, Heart Failure Working Group
    Full Title: DanHeart (H-HeFT / Met-HeFT)
    Medical condition: Heart Failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005025-25 Sponsor Protocol Number: NIMAO/2021-1/EB-01 Start Date*: 2022-06-08
    Sponsor Name:CHU DE NIMES
    Full Title: Evaluation de l’efficacité et de la sécurité de la Tamsulosine LP 0,4mg dans le traitement de la dysurie symptomatique de la femme atteinte de sclérose en plaques. Etude contrôlée randomisée en cro...
    Medical condition: Patientes majeures atteintes de sclérose en plaques (EDSS < 7,5) présentant une dysurie modérée à sévère (IPSS>7) par dyssynergie vésico-sphinctérienne authentifiée au bilan urodynamique complet.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002851-92 Sponsor Protocol Number: AN-EPI3334 Start Date*: 2016-09-08
    Sponsor Name:ANTHERA Pharmaceuticals, Inc.
    Full Title: An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis
    Medical condition: Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Completed) PL (Prematurely Ended) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001330-97 Sponsor Protocol Number: RB16.045 Start Date*: 2016-11-18
    Sponsor Name:CHRU de Brest
    Full Title: Prévention des Fausses Couches Spontanées Répétées par Hydroxychloroquine. Essai thérapeutique multicentrique, randomisé, en double insu, contre placebo.
    Medical condition: fausses couches spontanées
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Suspended by CA)
    Trial results: (No results available)
    EudraCT Number: 2021-002197-78 Sponsor Protocol Number: APHP200011 Start Date*: 2021-08-19
    Sponsor Name:Assistance Publique - Hôpitaux de Paris
    Full Title: Antimicrobial Stewardship For Ventilator Associated Pneumonia in Intensive Care Acronym: ASPIC
    Medical condition: ventilator associated neumonia in intensive care
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000519-18 Sponsor Protocol Number: P160906J Start Date*: 2019-04-09
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: PIMOC : Personalized targeted therapies in inflammatory complex multi organ disease
    Medical condition: Patients presenting inflammatory non classified disease targeting at least 2 organs involvement: skin, lymph nodes, hemopoietic system, joints, digestive tract. The disease has been resistant to at...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10062249 Skin inflammation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003958-23 Sponsor Protocol Number: 8154 Start Date*: 2021-10-21
    Sponsor Name:Hopitaux Universitaires de Strasbourg
    Full Title: A MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SPIRONOLACTONE FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS (RA)
    Medical condition: RHEUMATOID ARTHRITIS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001030-34 Sponsor Protocol Number: MC-0241 Start Date*: 2019-06-12
    Sponsor Name:Egis Pharmaceuticals PLC
    Full Title: A Prospective Open-label, Multicentric, Phase IV Trial to Compare the Efficacy of 10-Week Therapy of Ramipril and Indapamide SR Tablets Given Concomitantly with that of the Monotherapy of Ramipril ...
    Medical condition: hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001885-14 Sponsor Protocol Number: LOWBACK-SE Start Date*: 2019-08-06
    Sponsor Name:National Research, Development and Innovation Office
    Full Title: The prognostic value of Biomarkers and the Effect of Tolperisone in Acute low back pain and sciatic pain – BETA A Phase 3 investigator initiated study
    Medical condition: Acute low back pain with or withour radicular signs
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004245-37 Sponsor Protocol Number: UCDCRC/20/05 Start Date*: 2020-12-18
    Sponsor Name:University College Dublin
    Full Title: Randomised Placebo-Controlled Trial of Early Targeted Treatment of Patent Ductus Arteriosus with Paracetamol in Extremely Low Birth Weight Infants (ETAPA)
    Medical condition: Patent Ductus Arteriosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10034130 Patent ductus arteriosus PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002016-26 Sponsor Protocol Number: FBCSG-01-2007 Start Date*: 2007-08-08
    Sponsor Name:Finnish Breast Cancer Group
    Full Title: A randomized phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin, and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant ...
    Medical condition: Invasive early breast cancer that has been removed by surgery.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) SE (Completed) GB (GB - no longer in EU/EEA) IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004155-37 Sponsor Protocol Number: A01-115-02-EU Start Date*: 2020-07-30
    Sponsor Name:Aptabio Therapeutics, Inc
    Full Title: A randomized, Placebo-controlled, Double-blinded, Multi-centre, Phase 2 Study to Assess Safety, Tolerability and Renal Effects of APX-115 in Subjects with Type 2 Diabetes and Nephropathy
    Medical condition: diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002877-27 Sponsor Protocol Number: CTRIAL-IE-21-29/NRG-GY019 Start Date*: 2023-07-06
    Sponsor Name:Cancer Trials Ireland
    Full Title: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or P...
    Medical condition: Primary low-grade serous carcinoma of the ovary or peritoneum.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007107 Cancer of ovary LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026340 Malignant neoplasm of peritoneum, unspecified LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003218-42 Sponsor Protocol Number: RC18_0287 Start Date*: 2019-01-16
    Sponsor Name:CHU de Nantes
    Full Title: Phase 2 study evaluating MEchanisms of resistance on tumor tissue and Liquid biopsy in patients with EGFR mutated nonpretreated advanced Lung cancer Receiving OSimErtinib until and beyond radiologi...
    Medical condition: Locally advanced or metastatic Non-small-cell lung carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001783-28 Sponsor Protocol Number: BCG-COVID_HU_001 Start Date*: 2020-05-06
    Sponsor Name:National Korányi Institute of Pulmonology
    Full Title: REDUCING ABSENCE FROM WORK OF HEALTHCARE WORKERS DUE TO COVID-19 INFECTION BY BCG (BACILLUS CALMETTE-GUÉRIN) VACCINATION
    Medical condition: healthy volunteers working in the healthcare treating patients with new type of coronavirus (SARS-CoV-2) infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1748  1749  1750  1751  1752  1753  1754  1755  1756  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 28 19:09:44 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA